iGO Reports Annual and Fourth Quarter 2013 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
iGO Reports Annual and Fourth Quarter 2013 Financial Results

SCOTTSDALE, Ariz., March 21, 2014 (GLOBE NEWSWIRE) -- iGO, Inc. (OTCQB:IGOI) (the "Company" or "iGO"), a leading provider of eco-friendly power management solutions and accessories for mobile electronic devices, today reported financial results for the fiscal year and fourth quarter ended December 31, 2013.

Net revenue for the year ended December 31, 2013 was $16.9 million, as compared to $29.9 million for the year ended December 31, 2012. Net revenue for the fourth quarter of 2013 was $3.2 million as compared to $6.4 million in the same period of the prior year. The decline in revenue is primarily attributable to lower sales of power products.

Net loss for the year ended December 31, 2013 was $12.6 million or $4.30 per share, as compared to a net loss of $12.0 million, or $4.22 per share for the year ended December 31, 2012. Net loss for the quarter ended December 31, 2013 was $2.9 million, or $0.99 per share, as compared to a net loss of $3.9 million, or $1.34 per share, in the same quarter of the prior year. Net loss in the fourth quarter of 2012 included $1.4 million in write-downs in the value of goodwill and other intangible assets.

The Company had $9.0 million in cash, cash equivalents, and short-term investments, and no debt as of December 31, 2013.

About iGO, Inc.

iGO has been a leader in the mobile accessories industry since 1995, offering premium power solutions for laptop computers and electronic mobile devices that enhance the possibility of living life fully charged. iGO's universal chargers, batteries, and audio accessories offer support and performance that elevates the mobile consumer experience.

iGO's products are available at www.igo.com as well as through leading resellers and retailers.

iGO® is a registered trademark of iGO, Inc. All other trademarks or registered trademarks are the property of their respective owners.

iGO has adopted a Rights Agreement to deter acquisitions of 4.9% or more of the Company's common stock (subject to certain exceptions) by any group or person in order to protect the Company's ability to utilize its net loss carryforwards to reduce potential future federal income tax obligations.

On December 23, 2013, the Company, and Incipio Technologies, Inc. entered into an Inventory Purchase and License Agreement, pursuant to which Incipio will manage the manufacture, sales and distribution of the iGO® branded line of power supply products and accessories and other future products that maybe developed by the Company and Incipio.

Forward-looking statements

This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. The words "believe," "expect," "anticipate," "should," and other similar statements of our expectation identify forward-looking statements. These forward-looking statements are based largely on management's expectations and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks that could cause results to differ materially from those expressed in these forward-looking statements include, among others, the Company's new dependence on Incipio Technologies, Inc. (the "Licensee") and its ability to expand and diversify the customer base and product offerings for our products; the sufficiency of our revenue to absorb expenses; our dependence on large purchases from significant customers, notably WalMart; our ability to expand and diversify our customer base; increased focus of consumer electronics retailers on their own private label brands; fluctuations in our operating results because of: market acceptance of our products; our Licensee's ability to sell, service and support our products; the size and timing of customer orders; increases in product costs from our and our Licensee's suppliers; the timing of our new product and technology introductions and product enhancements relative to our competitors or changes in our or our competitors' pricing policies; our Licensee's ability to effectively manage inventory levels; delay or failure to fulfill orders for our products on a timely basis; our Licensee's inability to accurately forecast our contract manufacturing needs; difficulties with new product production implementation or supply chain; product defects and other product quality problems; the degree and rate of growth of the markets in which we compete and the accompanying demand for our products; our and our Licensee's ability to expand our internal and external sales forces and build the required infrastructure to meet anticipated growth; and seasonality of sales.

Additionally, other factors that could cause actual results to differ materially from those set forth in, contemplated by, or underlying these forward-looking statements are included in the Company's Quarterly Report on Form 10-K for the year ended December 31, 2013 under the heading "Risk Factors." In light of these risks and uncertainties, the forward-looking statements contained in this press release may not prove to be accurate. The Company undertakes no obligation to publicly update or revise any forward-looking statements, or any facts, events, or circumstances after the date hereof that may bear upon forward-looking statements. Additionally, the Company does not undertake any responsibility to update you on the occurrence of unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements.

iGO, Inc. and Subsidiaries        
Condensed Consolidated Statements of Operations        
(000's except per share data)        
(unaudited)        
             
             
  Three months ended   Year ended  
  December 31,    December 31,   
  2013 2012   2013 2012  
             
             
Net revenue  $ 3,210  $ 6,406    $ 16,928  $ 29,876  
             
Gross profit (loss)  (1,146)  894    (512)  5,283  
             
Selling, engineering and administrative expenses  1,785  3,010    11,631  14,497  
Asset impairment  --  1,443    456  1,443  
 Loss from operations  (2,931)  (3,559)    (12,599)  (10,657)  
Interest income (expense), net  --  2    5  12  
Other income (expense), net  14  (320)    28  (1,379)  
Net loss  $ (2,917)  $ (3,877)    $ (12,566)  $ (12,024)  
             
Basic and diluted net loss per share *  $ (0.99)  $ (1.34) *  $ (4.30)  $ (4.22) *
             
Basic and diluted weighted average common shares outstanding   2,945  2,885 *  2,921  2,852 *
             
* Common stock and per share information have been retroactively restated to reflect the 1-for-12 reverse stock split, effective January 28, 2013
 
 
iGO, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(000's)
(unaudited)
     
  December 31, December 31,
  2013 2012
     
ASSETS    
     
Cash and cash equivalents  $ 6,854  $ 8,229
Short-term investments  $ 2,142  $ 2,129
Accounts receivable, net  $ 1,065  $ 4,131
Inventories  $ 1,407  $ 8,376
Prepaid expenses and other current assets  $ 201  $ 336
Total current assets  11,669  23,201
Other assets, net  434  1,664
Total assets  $ 12,103  $ 24,865
     
     
LIABILITIES AND EQUITY    
     
Liabilities, excluding deferred revenue  $ 2,701  $ 3,494
Deferred revenue  --  307
Total liabilities  2,701  3,801
     
Total stockholders' equity  9,402  21,064
     
Total liabilities and equity  $ 12,103  $ 24,865
     

Terry R. Gibson 408-399-6490

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SVRN Taps Industry Vet Patrick O'Kain as COO

Updated Category News Views 54

SVRN Aims for New Heights with a Savvy Hire If there’s one thing veteran market-watchers like myself know, it’s that leadership shifts can tell you more about a company’s guts than any press release. SVRN (NASDAQ: SVRN), a name with one foot firmly in the world of digital assets, just snagged Patrick O’Kain for their COO spot. They're not playing around, folks,...

Continue Reading
Survey Reveals 'TDS' Impact on 2026 Midterm Elections

Updated Category News Views 70

Midterms and 'Trump Derangement Syndrome': What's the Deal? Every election season there's something new to raise eyebrows, and this time it's 'Trump Derangement Syndrome' (TDS) taking the spotlight. After the dust of the 2026 mid-terms started settling, it turns out there's more than just traditional candidate bickering shaping votes. Can you guess what's driving voters?...

Continue Reading
Sempra Shines with Robust Q3 2026 Financials

Updated Category News Views 0

Strong Q3 Numbers Set the Scene It’s not every day you see a company cough up numbers that speak volumes. Sempra’s third quarter for 2026 paints a picture of solid performance, boasting earnings of $877 million or $1.34 per diluted share per GAAP standards. That’s an eye-opener compared to the paltry $77 million or $0.12 per share they reported same time last year....

Continue Reading
Coastal Financial Faces Class Action Suit Over Securities

Updated Category News Views 78

Securities Law Tangles: Coastal Financial Hits a Snag There's no dodging it—Coastal Financial Corporation's dogged by a class action lawsuit, and investors need to sit up and take notice. This kind of legal fracas can hit the stock price like a brick through a window, especially when alleged securities law violations crop up. DJS Law Group's got the reins on this one,...

Continue Reading
Grant Davis Joins Assembly Health as CXO

Updated Category News Views 101

Shuffling Pieces in Healthcare Management Change is constant in healthcare management, folks, and it's all about finding the right puzzle pieces. That's what Assembly Health has done by welcoming Grant Davis as their new Chief Experience Officer (CXO). Yeah, you heard me right. It's not a CEO or a CFO, but the CXO role that's under the spotlight this time around, aiming...

Continue Reading
MAURE's Three-Year Mark: Crafting Home Elegance

Updated Category News Views 53

Brooklyn's Gem: MAURE Turns Three Over in Brooklyn, there's a brand bubbling with style called MAURE. Now, we're talking three years strong, surviving the wild bout of the retail scene with a firm two feet planted in home and gifting. The Vision Turned Reality When Maureen Cavalieri, a hospitality veteran since 2009, first tossed this spark into the wind in 2023, it...

Continue Reading
Dizal Unveils Promising Data at ASH 2026

Updated Category News Views 72

Pushing the Horizons in Hematological Research From the bustling streets of Shanghai to the global stage of the ASH 2026, Dizal has made its mark again. This year's presentations could very well shake up the hematological landscape, showcasing new possibilities for treatment strategies. Golidocitinib: A Game-Changer? Now here's a ticket we've been watching with some high...

Continue Reading
LOA Roofing's Growth Recap Taps Southstone's Backing

Updated Category News Views 107

Pardon my skepticism, but when a roofing company names itself Life of Abundance, you know they're aiming to hit it big or at least make you think they're onto something special. LOA Roofing and Construction, holding its ground as a major player in the Central Texas market, set the stage for more ambitious growth. And they found themselves a dance partner in Southstone...

Continue Reading
SKF's Industrial Push: Energy Efficiency at COP31

Updated Category News Views 17

SKF's Green Initiative: A Major Step Forward You ever find yourself in a room full of big players, each trying to outdo the other? That's the stage set for SKF at COP31, where they're not just strutting around showing off but actually offering some substance—a rarity in these highbrow gatherings. They're juicing up the talk around energy efficiency and circularity...

Continue Reading
Eli Lilly's Retatrutide Trials Signal Innovation

Updated Category News Views 48

Unpacking Lilly's Latest Rheumatology Innovations Lilly's taking the stage at ACR Convergence 2026 with a potent arsenal of data that’s got folks buzzing. The company’s put the pedal to the metal on understanding the intertwining chords of obesity and rheumatologic conditions, and boy, are they not messing around. Retatrutide: A Triple Threat in the Making Headlining...

Continue Reading

Top 5 Most Recently Viewed Articles

SKYX Technologies Expands Market Presence with Insider Investments

Updated Category News Views 166

SKYX Technologies' Corporate Developments SKYX Technologies, also known as SKYX (NASDAQ: SKYX), is taking significant strides in the smart technology sector. This dynamic company focuses on transforming homes and buildings into smarter, safer, and more advanced spaces. With a remarkable portfolio of over 97 issued and pending patents, SKYX aims to set a new standard in...

Continue Reading
Crinetics Pharmaceuticals Expands Workforce With Stock Options

Updated Category News Views 195

Crinetics Pharmaceuticals Enhances Employee Incentives In a recent announcement, Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), based in San Diego, revealed a significant step in enhancing employee incentives and strengthening its workforce. On October 10, 2025, the company’s Compensation Committee authorized the granting of stock options and restricted stock units...

Continue Reading
Manulife Investment Management Earns Top Recognition in Sustainable Finance

Updated Category News Views 199

Manulife Investment Management Recognized for Excellence In a significant acknowledgment of its leadership in sustainable finance, Manulife Investment Management (Manulife IM) has made it to the prestigious list of IPE Real Assets' Top 50 Natural Capital Managers. This recognition comes as the firm is gearing up for robust fundraising activities, with an exciting fund...

Continue Reading
Vaxart Reports Progress and Financial Performance for Q3 2025

Updated Category News Views 213

Vaxart’s Business Progress and Financial Results Overview Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, recently provided a significant update on its business and reported its financial outcomes for the third quarter of 2025. This latest communication showcases exciting developments in their oral recombinant vaccine platform, which is designed to...

Continue Reading
Madrigal Pharmaceuticals Marks Enrollment Milestone in NASH Study

Updated Category News Views 47

Madrigal Pharmaceuticals Achieves Enrollment Milestone in NASH Study Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company dedicated to developing innovative therapies for liver diseases, has announced a significant milestone in their MAESTRO-NASH OUTCOMES clinical trial. This study evaluates the efficacy of resmetirom in patients diagnosed with...

Continue Reading